Recently, finerenone, a new mineralocorticoid receptor antagonist (MRA), has proven to be effective in reducing kidney failure and kidney disease progression in patients with T2D with severely increased albuminuria and stage 3–4 CKD [56]. Here, NR3C2 is linked to type 2 diabetes mellitus.